Form 4: Nephros Inc. CFO Judy Krandel Reports Stock Option Grant
SEC Form 4 Filing
Judy Krandel, CFO of Nephros Inc., reports the acquisition of stock options and vesting schedules in a recent SEC filing.
Summary
- Judy Krandel, Chief Financial Officer of Nephros Inc., filed a Form 4 with the SEC on March 31, 2025.
- The filing reports a transaction date of March 27, 2025, where Krandel acquired 54,359 stock options with an exercise price of $1.68.
- These options vest in two tranches: 13,589 shares vest on March 27, 2026, and the remaining 40,770 shares vest quarterly in 12 equal amounts commencing on June 27, 2026.
- Krandel also holds previously reported options to purchase 122,524 shares with an exercise price of $1.71, some of which are vesting.
- The filing also includes a power of attorney, effective November 2, 2023, authorizing Christopher Melsha and Edward Peilen to act on Krandel's behalf for Section 16 filings related to Nephros Inc. securities.
Sentiment
Score: 7
Explanation: The document is a routine SEC filing related to executive compensation. It's generally neutral to slightly positive as it indicates alignment of management interests with shareholders.
Positives
- The grant of stock options to the CFO aligns her interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CFO.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedules of the stock options suggest an expectation of continued employment and contribution from the CFO.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology and medical device industries, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the medical device industry.
- Companies like Baxter International and Medtronic also utilize stock options as part of their executive compensation plans.
- The vesting schedules and exercise prices are generally in line with industry norms for companies of similar size and stage of development.
Stakeholder Impact
- Shareholders: The stock option grant aligns the CFO's interests with increasing shareholder value.
- Employees: The grant could have a positive impact on employee morale as it shows the company is investing in its leadership.
Key Dates
| Date | Description |
|---|---|
| 2023-11-02 | Effective date of the Power of Attorney. |
| 2024-11-01 | Initial vesting date for previously held options (30,631 shares). |
| 2025-02-01 | Commencement of quarterly vesting for remaining previously held options (91,893 shares). |
| 2025-03-27 | Transaction date for the acquisition of 54,359 stock options. |
| 2025-03-31 | Date of SEC filing (Form 4). |
| 2026-03-27 | Vesting date for 13,589 shares of the newly acquired options. |
| 2026-06-27 | Commencement of quarterly vesting for the remaining 40,770 shares of the newly acquired options. |
| 2035-03-27 | Expiration date for the newly acquired options. |
Keywords
Nephros Inc., Judy Krandel, stock options, Form 4, SEC filing, beneficial ownership, power of attorney, vesting schedule, Chief Financial Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.